指南与共识脑血管病神经重症与神经感染

结合珠蛋白治疗动脉瘤性蛛网膜下腔出血:临床转化综述与专家共识

Haptoglobin Treatment for Aneurysmal Subarachnoid Hemorrhage: Review and Expert Consensus on Clinical Translation.
指南 / 共识 · Stroke · 2023-05-26

动脉瘤性蛛网膜下腔出血(aSAH)预后改善需求未满足。本文综述鞘内补充结合珠蛋白的治疗进展,并通过德尔菲法形成全球共识:细胞外血红蛋白是继发性脑损伤的关键决定因素,结合珠蛋白可不可逆结合游离血红蛋白;多数专家认为该领域已准备好开展早期临床试验。

要点

  • aSAH后红细胞裂解释放游离血红蛋白,是继发性脑损伤和长期临床结局的强决定因素。
  • 结合珠蛋白不可逆结合游离血红蛋白,阻止其进入脑实质和脑动脉一氧化氮敏感功能区。
  • 德尔菲共识认为进一步临床前工作不是优先事项,多数认为该领域已准备好开展早期试验。

核心结论

  • 这些结果突显了针对aSAH开展颅内结合珠蛋白早期试验的必要性,以及临床学科在全球范围内早期参与临床转化早期阶段的价值。

研究设计与样本

  • 本特别报告通过综述现有知识与进展,并采用德尔菲法形成关于细胞外血红蛋白病理生理作用及血红蛋白清除治疗临床转化研究优先级的全球共识。
  • 来自5大洲的执业临床医生(n=72)和科学专家(n=28)参与了德尔菲研究。

主要发现

  • 炎症、微血管痉挛、初始颅内压升高和一氧化氮信号中断被认为是对结局最重要的病理生理通路。
  • 游离血红蛋白被认为主要在与铁毒性、氧化应激、一氧化氮和炎症相关的通路中起重要作用。
  • 虽然有用,但共识认为进一步的临床前工作不是优先事项,大多数人认为该领域已准备好开展早期试验。
  • 最高研究优先级涉及确认结合珠蛋白的预期安全性、个体化与标准给药、治疗时机、药代动力学、药效动力学和结局指标选择。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating form of stroke frequently affecting young to middle-aged adults, with an unmet need to improve outcome. This special report focusses on the development of intrathecal haptoglobin supplementation as a treatment by reviewing current knowledge and progress, arriving at a Delphi-based global consensus regarding the pathophysiological role of extracellular hemoglobin and research priorities for clinical translation of hemoglobin-scavenging therapeutics. After aneurysmal subarachnoid hemorrhage, erythrocyte lysis generates cell-free hemoglobin in the cerebrospinal fluid, which is a strong determinant of secondary brain injury and long-term clinical outcome. Haptoglobin is the body's first-line defense against cell-free hemoglobin by binding it irreversibly, preventing translocation of hemoglobin into the brain parenchyma and nitric oxide-sensitive functional compartments of cerebral arteries. In mouse and sheep models, intraventricular administration of haptoglobin reversed hemoglobin-induced clinical, histological, and biochemical features of human aneurysmal subarachnoid hemorrhage. Clinical translation of this strategy imposes unique challenges set by the novel mode of action and the anticipated need for intrathecal drug administration, necessitating early input from stakeholders. Practising clinicians (n=72) and scientific experts (n=28) from 5 continents participated in the Delphi study. Inflammation, microvascular spasm, initial intracranial pressure increase, and disruption of nitric oxide signaling were deemed the most important pathophysiological pathways determining outcome. Cell-free hemoglobin was thought to play an important role mostly in pathways related to iron toxicity, oxidative stress, nitric oxide, and inflammation. While useful, there was consensus that further preclinical work was not a priority, with most believing the field was ready for an early phase trial. The highest research priorities were related to confirming haptoglobin's anticipated safety, individualized versus standard dosing, timing of treatment, pharmacokinetics, pharmacodynamics, and outcome measure selection. These results highlight the need for early phase trials of intracranial haptoglobin for aneurysmal subarachnoid hemorrhage, and the value of early input from clinical disciplines on a global scale during the early stages of clinical translation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Galea I, Bandyopadhyay S, Bulters D, et al. Haptoglobin Treatment for Aneurysmal Subarachnoid Hemorrhage: Review and Expert Consensus on Clinical Translation. Stroke. 2023. PMID: 37232189. doi:10.1161/STROKEAHA.123.040205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。